The 8th China International Import Expo will be held in Shanghai from November 5th to 10th. In the six major corporate business exhibitions, the medical equipment and healthcare exhibition area has once again become the "showcase" for cutting-edge achievements and new product launches in the global medical industry. Over the years, with the release of one batch after another of healthy and good products, it not only reflects the "speed of China", but also reflects the "temperature of China", fully safeguarding life and health. Innovative products are constantly emerging to meet more health needs. This year, Siemens Healthineers' exhibition area will be the largest in the company's history at the CIIE, reaching 1000 square meters. As a "fully enrolled student in the CIIE" program, Siemens Healthineers brings its first ever high-speed spectral angiography system, the ARTIS icono ceiling Xpand, which was first exhibited in Asia. It can clearly capture small tumors that were previously difficult to detect within 2.5 seconds, helping doctors complete minimally invasive treatments with sub millimeter level ultra-high precision. At the same time, it integrates multiple AI technologies to provide refined treatment for liver cancer and lung cancer patients. At the Medtronic exhibition area, there will be a lightweight and compact product that can "listen to the sounds emitted by the body", sense changes in spinal cord biological signals under different movements, and automatically adjust stimulation in real time, providing continuous treatment for chronic pain patients. In addition to medical devices, new drugs are also a hot topic of concern every year. This year, Novartis will showcase nearly 20 innovative products covering four core therapeutic fields: cardiovascular, renal and metabolic, oncology, immunology, and neuroscience. At the same time, an immersive interactive experience will be set up, where viewers can wear spatial computing display devices to "travel" to the microscopic world and observe the journey of innovative drugs in the human body from a first person perspective. In addition, in addition to showcasing a series of innovative projects, Lilly has created two interactive sections, "Memory Cafe" and "Body Resistance Decoding Exhibition," to address public health challenges such as "aging population" and "obesity issues," in order to enhance the public's scientific understanding of Alzheimer's disease and obesity. The transformation of exhibits into commodities is accelerating its implementation. AVEIR making its debut at the 6th CIIE? The DR dual chamber implantable leadless cardiac pacing system has been approved for market in China this year and has undergone implantation surgery in multiple hospitals across the country, benefiting more patients. Pan Wenqi, chief physician of the Department of Cardiology at Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine, who helped patients implant the product, introduced that pacemakers are an effective way to treat severe bradycardia. Compared with traditional pacemakers, this product can not only achieve synchronous communication between atria and ventricles, simulate natural heart activity to ensure accurate pacing, but also avoid the risk of infection caused by pocket bags and the risk of wire breakage caused by lead wear. More and more companies are witnessing their own 'exhibits turning into commodities'. The CIIE is a key platform for us to showcase our innovative achievements, gain insights into local needs, and deepen cooperation and win-win outcomes, "said Gao Haoting, President and CEO of Boehringer Ingelheim Greater China, a German pharmaceutical company. Thanks to the accelerated review and approval of new drugs in China and the company's implementation of the" China Key "strategy, the innovative lung cancer drug" Shenghetu "showcased at last year's CIIE has been approved simultaneously in China and the United States this summer. It is worth mentioning that in order to help innovative drugs land on the "last mile", Shangyao Cloud Health, as a comprehensive service provider for innovative drugs outside the hospital market, integrates "professional pharmacy+digital patient service platform+payment innovation" outside the exhibition to ensure that patients can buy and use them well from "drug delivery" to "health management". Transform from an exhibitor to an investor and expand your "circle of friends". By March 2025, Yikeda will achieve localized production of all its products; On May 8th, Roche Pharmaceuticals China announced an investment of 2.04 billion yuan to build a new biopharmaceutical production base in Shanghai; On October 25th, Medtronic's first digital medical innovation base in China landed in the Beijing International Medical Innovation Park... Roche Pharmaceuticals China President Bian Xin stated that as an important window for China's high-level opening-up and a global innovation sharing platform, the CIIE has provided an irreplaceable strategic stage for foreign-funded enterprises deeply rooted in China. The continuously optimized business environment and innovation ecosystem in China provide a fertile ground for foreign-funded enterprises to take root and grow. The company will continue to increase investment and deepen its layout in China, and work together with ecological partners to promote collaborative innovation in the medical and health field. Wang Jinghua, managing partner of Medtronic China Fund, said that the company not only focuses on the development of local value chain, but also focuses on local innovation. Medtronic China Fund has invested in more than 10 medical technology startups and recently made a strategic stake in Xinhuan Technology. We look forward to multi-level strategic cooperation in areas such as intracardiac ultrasound in the future, bringing high-quality medical solutions to China and even the world. We deeply feel the continuous optimization of China's business environment, and in the past three years, we have reached more than 20 cooperation agreements at the CIIE. ”Jin Fangqian, Global Vice President and General Manager of Gilead Science in China, said that he looks forward to using the CIIE as an important platform to expand his "circle of friends" and resonate with China's new journey of the 15th Five Year Plan. (New Society)